Skip to content

Clinical study of faropenem sodium to acute uncomplicated cystitis

Clinical study of faropenem sodium to acute uncomplicated cystitis - Clinical study of faropenem sodium to acute uncomplicated cystitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004307
Enrollment
300
Registered
2010-10-01
Start date
2010-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute uncomplicated cystitis

Interventions

FRPM 200mg twice a day (600mg/day)is administrated to patients for 3 days FRPM 200mg twice a day (600mg/day)is administrated to patients for 7 days

Sponsors

npo crec net
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Female outpatients over the age of 20,who are diagnosed with acute uncomplicated cystitis. Patients who had any symptoms of pain on urination,frequent urination,urgency of urination or lower abdominal pain. Patients who had pyuria with any categories below before the treatment;more than 10 WBC/mm3 in non-centrifuged urine specimen by testing equipment or calculated board, positive on non-centrifuged urine specimen by urine test strip or more than 5 WBC/mm3 in the urinary sediments. Patients who had bacteriuria with more than 103 cfu/ml (Staphylococcus sp., Enterococcus faecalis, Streptococcus agalactiae or Enterobacteriaceae) before the treatment.

Exclusion criteria

Exclusion criteria: 1.Patients infected with bacteria which can not expected efficacy of FRPM. 2.Patients with allergy to penicillins or chaparosporins. 3.Pregnant or lactating patients. 4.Patients with severe heart, liver or renal dysfunction. 5.Patients who had antimicrobial treatemt in 10 days

Design outcomes

Primary

MeasureTime frame
Microbiological efficacy on 5-9 days after the finishing the administration of FRPM

Secondary

MeasureTime frame
Clinical efficacy of FRPM Evaluation of recurrence after treatment Safety of FRPM

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026